Discovering APOF: A Key Regulator of Lipid Metabolism (G319)

Target Name: APOF

NCBI ID: G319

APOF

Discovering APOF: A Key Regulator of Lipid Metabolism

APOF (Lipid Transfer Inhibitor Protein) is a protein that is expressed in various tissues throughout the body, including the liver, heart, and kidneys. It is a key regulator of lipid metabolism and has been shown to play a crucial role in the treatment of various diseases, including heart disease and obesity. As a result, APOF has potential as a drug target or biomarker in a variety of settings.

The discovery and characterization of APOF was made by a team of researchers at the University of California, San Diego. The team identified a protein that was highly expressed in the liver and heart and was shown to be involved in lipid metabolism. The protein was named APOF and was found to be a key regulator of lipid transfer across cell membranes.

Since its discovery, APOF has been shown to have a wide range of potential applications in medicine. For example, studies have shown that high levels of APOF expression are associated with an increased risk of heart disease and obesity. Additionally, the protein has been shown to be involved in the development of certain diseases, including cancer.

As a result, APOF has generated a lot of interest as a potential drug target or biomarker. Researchers are actively searching for ways to use APOF as a treatment for various diseases, including heart disease, cancer, and obesity. In particular, studies have shown that APOF can be used to improve lipid profiles in patients with heart disease and to reduce the risk of certain diseases, such as cancer.

In addition to its potential as a drug or biomarker, APOF has also been shown to have a number of potential therapeutic benefits. For example, the protein has been shown to have anti-inflammatory effects, which can help to reduce the risk of certain diseases. Additionally, APOF has been shown to have anti-cancer effects, which can help to reduce the risk of cancer recurrence.

Overall, APOF is a protein that has a wide range of potential applications in medicine, including its potential as a drug target or biomarker. Further research is needed to fully understand the protein's role in disease and its potential as a therapeutic agent.

Protein Name: Apolipoprotein F

Functions: Minor apolipoprotein that associates with LDL. Inhibits cholesteryl ester transfer protein (CETP) activity and appears to be an important regulator of cholesterol transport. Also associates to a lesser degree with VLDL, Apo-AI and Apo-AII

The "APOF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APOF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets